Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
-
La Jolla Pharma (LJPC) PT Raised to $90 at Chardan Capital Markets Following Robust LJPC-501 Phase 3 Topline Results
-
La Jolla Pharma (LJPC) a Top Pick at Chardan Capital Markets Into Data
-
La Jolla Pharmaceutical (LJPC) Closes 2.9M Common Stock Offering
-
La Jolla Pharmaceutical Company Closes Offering of Common Stock
-
La Jolla Pharmaceutical (LJPC) Prices 2.55M Common Stock Offering at $38/Share
-
La Jolla Pharmaceutical Company Announces Pricing of Underwritten Offering of Common Stock
-
Notable 52-Week Highs and Lows 9/8: (JBLU) (NAVB) (LJPC) High; (GPRO) (YGE) (VNCE) Low
-
Unusual 11 Mid-Day Movers 9/8: (CAPN) (TE) (LJPC) Higher; (ACI) (YGE) (NOR) Lower
-
Chardan Capital Boosts PT on La Jolla Pharma (LJPC) to $80 Following CEO Meeting
-
La Jolla Pharma (LJPC) PT Raised to $60 at Chardan Capital Markets
-
Chardan Capital Resumes La Jolla Pharma (LJPC) at Buy; Sees Sales Over $1B by FY22
-
La Jolla Pharma (LJPC) Poised to Open Lower After 5.4M Offering Prices at $10.50/Share
-
La Jolla Pharmaceutical (LJPC) Prices 4.8M Common Offering at $10.50/Share
-
UPDATE: La Jolla Pharma (LJPC) PT Raised to $54 at Chardan
-
UPDATE: Chardan Capital Markets Starts La Jolla Pharma (LJPC) at Buy, PT $32
-
Notable Analyst Rating Changes 03/06: (BIIB) (COG) (HA) Upgraded; (AUXL) (LOV) (ARTC) Downgraded

